STAT+: Gilead’s remdesivir sales are surging, but investors aren’t impressed
A lot more Covid-19 patients in the U.S. are being treated with Gilead Sciences’ remdesivir because of the accelerating case counts. But even with sales of the medicine surging, investors are not impressed.
Shares of Gilead, which markets remdesivir as Veklury, closed down Monday by just under 1% to $62.51 despite the biotech announcing updated and sharply higher product sales guidance for 2020, which included anticipated Veklury sales of $2.8 billion.
Continue to STAT+ to read the full story…
